Cyclacel Pharma (CYCC) Submits Answers to Declaratory Judgement Complaint Filed by Celgene (CELG)

Article Stock Quotes (2) Comments (0)

Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) today announced that it filed its Answer and Counterclaims to the declaratory judgment complaint filed by Celgene Corporation (Nasdaq: CELG). Cyclacel has filed counterclaims charging Celgene with infringement of each of four Cyclacel-owned patents and seeks damages for Celgene's infringement as well as injunctive relief. The four patents directly involve the use and administration of Celgene's ISTODAX® (romidepsin for injection) product.

The declaratory judgment complaint seeks to have the four Cyclacel patents, which claim the use of romidepsin for injection in T-cell lymphomas, declared invalid and not infringed by Celgene's products.

The four Cyclacel patents which are the subject of this action do not involve Cyclacel's clinical development candidates or its commercial products.

You May Also Be Interested In

• Salix Pharma (SLXP) Reports Positive Results From Two Budesonide Foam Phase 3s
• Boston Scientific (BSX) Reports Positive Results from NG PROMUS, EVOLVE
• J. C. Penney (JCP) Enters $2.25B Secured Term Loan Facility

Create E-mail Alert Related Categories

Corporate News, FDA

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?